eligibility_summary
Adults 18–75 with pathology‑confirmed cancer (solid tumors/lymphoma), ECOG 0–2, >6‑mo survival, adequate marrow/liver/kidney/coag labs, tumor positive for ≥1: Mesothelin, NKG2D, HER2, CD276, CD19, BCMA. Exclude: immunotherapy in past month, transplant, pregnant/lactating, active infection, HBV DNA≥2000 or HIV/HCV/syphilis+, active brain mets, 2nd malignancy, severe autoimmune on chronic immunosuppression, cardiac dz (NYHA≥2, uncontrolled HTN, myocarditis, MI<1y), active bleeding/thrombosis.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial NCT06515626 tests genetically modified T cells (CAR‑T), a cellular gene therapy/biologic. Intervention: CAR‑T cell reinfusion (1–10×10^6 cells/kg, mainly IV, local delivery optional). Mechanism of action: patient T cells are engineered with chimeric antigen receptors to recognize tumor antigens in an MHC‑independent manner, triggering T‑cell activation (CD3ζ/costimulatory signaling), cytokine release, and cytotoxic killing of cancer cells. Targets/cells/pathways: tumor cells expressing selected antigens—Mesothelin, HER2, CD276 (B7‑H3), CD19, BCMA, or NKG2D‑ligand pathway (stress ligands such as MICA/MICB/ULBPs). This spans solid tumors (e.g., mesothelin, HER2, B7‑H3) and hematologic targets (CD19, BCMA), with NKG2D‑based CARs engaging stress‑induced ligand pathways across tumors.